Where is Xontogeny's headquarters located?

Xontogeny's headquarters is located in Boston (United States).

How big is Xontogeny's investment team?

Xontogeny has a team of 18, including 5 partners.

How many companies has Xontogeny invested in?

Xontogeny has invested in 28 companies, including Forge Biologics & Zucara Therapeutics.

Which companies has Xontogeny invested in lately?

Zucara Therapeutics & CereVasc are the latest investments by Xontogeny.

How many exits has Xontogeny been involved in?

Xontogeny's portfolio has seen 3 IPOs and 5 acquisitions.

Xontogeny - 2026 Investor Profile, Portfolio, Team & Investment Trends

Xontogeny, an accelerator and incubator program founded in 2016, is based in Boston, United States. With a presence in 4 countries, it has supported around 28 startups in sectors like Life Sciences, High Tech. As of Jan 2026, Xontogeny has witnessed 8 portfolio exits. Most notable companies in its portfolio include Forge Biologics, Zucara Therapeutics and Cargo Therapeutics. The program is backed by a team of 18 people who primarily support Series A startups based in United States. Its latest investment was a $20M Series B round in Zucara Therapeutics on Nov 12, 2024 along with Sanofi.

Key Metrics

Founded Year

2016

Location

Boston, United States

Portfolio Companies

Forge Biologics, Zucara Therapeutics & 26 more

Sectors of Investment

Life Sciences, High Tech & 3 more

Stages of Investment

Series A, Seed & 3 more

Locations of Investment

United States, Canada & 2 more

View Xontogeny's full profile

Xontogeny has a portfolio of 28 companies. Their most notable investments are in Quellis Biosciences and Surf Bio.Their portfolio spans across United States, Canada, China and 1 more locations. They have invested in Life Sciences, High Tech, Consumer and 2 other sectors, across stages such as Series A, Seed and 3 more. Here is the list of top investments by Xontogeny:

1. Forge Biologics

Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.

Key facts about Forge Biologics

Founded Year: 2020
Location: Columbus (United States)
Stage: Acquired
Total Funding till date: $330M
Employee Count: 118 as on Dec 31, 2021
Investors: Aisling Capital, Citadel and 7 Others
Latest Funding Round: Series C, Sep 12, 2022, $*****
Highlight: Acquired

2. Zucara Therapeutics

Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing a novel drug for the treatment of hypoglycemia associated with insulin therapy. Their lead candidate PRL-2903 works via the chronic receptor antagonism through which they block somatostatin type 2 (SSTR2) receptors on α-cells in the pancreas.

Key facts about Zucara Therapeutics

Founded Year: 2015
Location: Vancouver (Canada)
Stage: Series B
Total Funding till date: $50.8M
Employee Count: 12 as on Dec 31, 2024
Investors: Sanofi, Perceptive Advisors and 14 Others
Latest Funding Round: Series B, Feb 03, 2025, $*****
Highlight: Editors' Pick

3. Cargo Therapeutics

Developer of cell-based therapeutics for cancer treatment. It offers CAR T-cell therapies which include CD22 CAR T, and Multi-Specific CAR T drug candidates for the treatment of hematological malignancies, and solid tumors.

Key facts about Cargo Therapeutics

Founded Year: 2021
Location: San Mateo (United States)
Stage: Acquired
Total Funding till date: $200M
Employee Count: 42 as on Dec 31, 2022
Investors: T. Rowe Price, Janus Henderson Investors and 13 Others
Latest Funding Round: Series A, Feb 09, 2023, $*****
Highlight: Acquired

4. Astria

Developer of therapeutics for rare diseases. It offers a lead candidate STAR-0215 which is a monoclonal antibody inhibitor of plasma kallikrein for the treatment of hereditary angioedema, and allergic and immunological diseases.

Key facts about Astria

Founded Year: 2008
Location: Boston (United States)
Stage: Acquired
Total Funding till date: $117M
Employee Count: 42 as on Jul 01, 2024
Investors: MedImmune Ventures, Perceptive Advisors and 3 Others
Latest Funding Round: Post IPO, Jan 29, 2021, $*****
Highlight: Acquired

5. Apogee Therapeutics

Developer of therapeutics for immunological and inflammatory disorders. The company is advancing a pipeline of product candidates, which includes APG777, for the treatment of immunological, inflammatory disorders, and autoimmune disorders.

Key facts about Apogee Therapeutics

Founded Year: 2022
Location: Waltham (United States)
Stage: Public
Total Funding till date: $149M
Employee Count: 91 as on Mar 31, 2024
Investors: Access Industries, Orbimed and 5 Others
Latest Funding Round: Series B, Dec 07, 2022, $*****
Highlight: Public

View the full list of portfolio companies

Xontogeny has invested in 28 companies over the last 9 years, with an average of 3 new investments annually in the last 5 years. Its most recent first time investment was in Zucara Therapeutics and most recent follow-on round was in CereVasc.

Here are Xontogeny's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	0	0	0
2024	3	1	4
2023	4	1	5
2022	4	1	5
2021	6	1	7
2020	3	0	3
2019	0	0	0
2018	0	0	0
2017	2	0	2

View all investments by Xontogeny

Xontogeny has made 11 investments in Series A stage with an average round size of $55.9M, 7 investments in Seed stage with an average round size of $6.59M, 2 investments in Series B stage with an average round size of $89M, 1 investment in Series C stage with an average round size of $189M and 1 investment in Unattributed stage.

Here are Xontogeny's investments by stage:

Stage of entry	No. of Investments
Series A	11
Seed	7
Series B	2
Series C	1
Unattributed	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Consumer and Environment. Notably, it has invested in 27 Enterprise (B2B) companies, 27 Tech companies and 1 Tech hardware company.

Here are Xontogeny's investments by sector:

Sector	No. of Investments
Life Sciences	21
High Tech	2
Sustainability Tech	2
Consumer	1
Environment	1
Others	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has made most investments in United States (20), followed by Canada where it has made 1 investment.

Here are Xontogeny's investments by geography:

Country	No. of Investments
United States	20
Canada	1
Switzerland	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has not made any investment in 2026 so far.

Here are the most recent investments by Xontogeny:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Nov 12, 2024	Zucara Therapeutics	Canada	Series B	3172	Sanofi
May 13, 2024	CereVasc	United States	Series B	3445	Bain Capital
Apr 24, 2024	Adaptilens	United States	Series A	9879	Pillar VC [+1]
Apr 03, 2024	Neurosterix	Switzerland	Series A	2262	Perceptive Advisors [+1]
Sep 27, 2023	Avalyn Pharma	United States	Series C	1187	Perceptive Advisors [+13]

See more recent investments made by Xontogeny

3 of Xontogeny's portfolio companies have become public. Apogee Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2023 at marketcap of $809M and LianBio got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $325M.

Here are Xontogeny's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Apogee Therapeutics	Jul 14, 2023	-	-	6566
LianBio	Nov 01, 2021	-	-	9986
Solid Biosciences	Jan 26, 2018	-	-	4103

View more details about public companies in Xontogeny's portfolio

5 companies from Xontogeny's portfolio have been acquired. The most recent acquisition were Astria in Oct 2025 by BioCryst for $920M.

Here are Xontogeny's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Astria	Oct 17, 2025	-	-	5644
Cargo Therapeutics	Jul 08, 2025	Feb 09, 2023	Series A	7356
Landos Biopharma	Mar 25, 2024	-	-	8836
Forge Biologics	Nov 13, 2023	Jul 21, 2020	Series A	4044
Quellis Biosciences	Jan 29, 2021	Nov 2017	Seed	4371

View all acquired companies in Xontogeny's portfolio

Xontogeny has a team of 18 members including 5 Partners and 4 Principals located in United States. Xontogeny's team sits on the board of 1 company.

Here is a list of top team members in Xontogeny:

Name	Designation	Location	Board Memberships	Contact Details
Chris Garabedian	Partner	Boston	Zucara Therapeutics	1 Email
Adam Stone	Partner	New York City	-	-
Gianna Hoffman Luca	Partner	San Francisco	-	-
Fred Callori	Partner	Boston	-	-
Joseph Edelman	Partner	New York City	-	-
Heather Petty	Principal	The Colony	-	-
Takeru Furuya	Principal	Cambridge	-	-
Gianna Hoffman-Luca	Principal	San Francisco	-	1 Email
Maggie Clarkeson-Carroll	Principal	New York City	-	-

View team details of Xontogeny

Over the past 9 years, 106 investors have co-invested in Xontogeny's portfolio companies. This includes funds and angels.

Invested before Xontogeny: HHS, National Research Council Canada and 43 others have invested in rounds before Xontogeny. There are 4 companies where HHS has invested before Xontogeny and 1 company where National Research Council Canada has invested before Xontogeny.
Top Co-investors of Xontogeny: 47 investors entered a company along with Xontogeny. These include investors like Perceptive Advisors (4 companies).
Invested after Xontogeny: A total of 14 investors have invested in Xontogeny's portfolio after their investments. Top Investors include Perceptive Advisors (3 companies) and Citadel (2 companies).